IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
批准号:
2048911
负责人:
HARVEY L OZER
金额:
$29.36万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-12-01 至 1997-07-31
关键词:
DNA replication RNA cell cycle cell differentiation cell line chromosome aberrations clone cells complementary DNA diploidy fibroblasts gene expression genetic library genetic manipulation genetic mapping human tissue in situ hybridization karyotype laboratory mouse molecular cloning mutagens natural gene amplification northern blottings nucleic acid sequence polymerase chain reaction protooncogene simian virus 40 tissue /cell culture tumor suppressor genes virus antigen
中文摘要
描述(改编自申请人的摘要):人类二倍体细胞
从正常组织派生的人在体内经历了特有的生长模式
细胞培养,以非复制阶段结束。元胞模型
衰老的研究表明,这种模式与
生物体在体内的行为;因此,术语衰老。人类
DNA体外转化的二倍体成纤维细胞
病毒SV40已被发现可以克服这种现象(即永生)
在低频率下。调查人员已经分离出一系列SV40-
使用含有A或A的来源缺陷病毒基因组转化HF
野生型T抗原(SV/HF)或tsA58抗原(SVtsA/HF)。在每个系统中,
他们随后分离出不朽的衍生品,以便进行比较
学习。数据与以下两步模型最为一致
永垂不朽。两者都需要SV40大T抗原(LT)功能
温度依赖性(Ts)细胞增殖所证明的阶段
长生不老和长生不老SVtsA/HF-A的TS-LT功能一致
细胞。在步骤1中,LT在很大程度上起着促有丝分裂的作用
通过它与细胞蛋白如pRb和p53的相互作用。第二步,
这是特定于不朽的,涉及到功能的改变
直接依赖于LT。染色体长臂上的重排
6(6q21)与抑制基因失活一致
具体与步骤2相关联。
申请人通过以下途径确定了基因表达的变化
永生与永生基因文库的差异杂交
SV40-转化子,并建议鉴定涉及的基因。这个
研究人员首先将重点放在那些表达
在几个匹配的不朽转化子中减少,与他们的
亲本永生前转化体,最符合隐性
后者在细胞杂交中的性质。还提出了策略以
确定6q上的致病基因。在这两种情况下,基因都被识别出来
将被评估为对永生细胞系的生长抑制,
与衰老和致癌有关的现象。
研究人员还发现,细胞原癌基因c-myb
在一种永生的HF细胞系中被诱导,该细胞系由完整的而不是
截断LT。他们建议评估病毒和细胞功能
负责是因为c-myb对细胞增殖和
作为在不朽的SV40转化子中过度表达的基因的原型。
英文摘要
DESCRIPTION (Adapted from the applicant's abstract): Human diploid cells
derived from normal tissue undergo a characteristic pattern of growth in
cell culture, ending with a non-replicative phase. Models of cellular
aging have been developed which suggest analogy between this pattern and
behavior of the organism in vivo; hence, the term senescence. Human
diploid fibroblasts (HF) which have been transformed in vitro by the DNA
virus SV40 have been found to overcome this phenomenon (i.e., immortalize)
at low frequency. The investigators have isolated a series of SV40-
transformed HF using origin-defective viral genomes containing either a
wild-type T antigen (SV/HF) or that of tsA58 (SVtsA/HF). In each system,
they have subsequently isolated immortalized derivatives for comparative
studies. The data are most consistent with a 2-step model for
immortalization. SV40 large T antigen(LT) function is required in both
stages, as demonstrated by temperature-dependent (ts) cell proliferation
in concordance with ts LT function in preimmortal and immortal SVtsA/HF-A
cells. At step 1, LT functions as a mitogenic agent, in large part
through its interaction with cellular proteins as pRb and p53. Step 2,
which is specific to immortalization, involves changes in functions not
directly dependent on LT. A rearrangement on the long arm of chromosome
6 (6q21) consistent with inactivation of a suppressor gene has been found
to be specifically associated with step 2.
The applicant has identified changes in gene expression through
differential hybridization with cDNA libraries of preimmortal and immortal
SV40- transformants and propose to identify the genes involved. The
investigator will focus initially on those genes whose expression is
reduced in several matched immortal transformants as compared to their
parental preimmortal transformants, most consistent with the recessive
nature of the latter in cell hybrids. Strategies are also presented to
identify the responsible gene on 6q. In both cases, the genes identified
will be assessed for growth suppression of immortal cell lines, a
phenomenon relevant to both senescence and carcinogenesis.
The investigators have also found that the cellular proto-oncogene c-myb
is induced in an immortal HF cell line transformed by an intact but not a
truncated LT. They propose to assess the viral and cellular functions
responsible because of the importance of c-myb to cell proliferation and
as a prototype of genes overexpressed in immortal SV40-transformants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interdisciplinary Training Program in Cancer Research
-
批准号:8471539
-
项目类别:
-
资助金额:$2.04万
-
财政年份:2010
-
负责人:HARVEY L OZER
-
依托单位:
Interdisciplinary Training Program in Cancer Research
-
批准号:8065531
-
项目类别:
-
资助金额:$19.61万
-
财政年份:2010
-
负责人:HARVEY L OZER
-
依托单位:
Interdisciplinary Training Program in Cancer Research
-
批准号:8701009
-
项目类别:
-
资助金额:$6.57万
-
财政年份:2010
-
负责人:HARVEY L OZER
-
依托单位:
Interdisciplinary Training Program in Cancer Research
-
批准号:8260872
-
项目类别:
-
资助金额:$20.12万
-
财政年份:2010
-
负责人:HARVEY L OZER
-
依托单位:
Interdisciplinary Training Program in Cancer Research
-
批准号:7763526
-
项目类别:
-
资助金额:$18.77万
-
财政年份:2010
-
负责人:HARVEY L OZER
-
依托单位:
GENE EXPRESSION IN SV40-TRANSFORMED HUMAN FIBROBLASTS
-
批准号:6216387
-
项目类别:
-
资助金额:$11.95万
-
财政年份:1999
-
负责人:HARVEY L OZER
-
依托单位:
GENE EXPRESSION IN SV40-TRANSFORMED HUMAN FIBROBLASTS
-
批准号:6200940
-
项目类别:
-
资助金额:$11.95万
-
财政年份:1999
-
负责人:HARVEY L OZER
-
依托单位:
GENE EXPRESSION IN SV40-TRANSFORMED HUMAN FIBROBLASTS
-
批准号:6097820
-
项目类别:
-
资助金额:$11.95万
-
财政年份:1998
-
负责人:HARVEY L OZER
-
依托单位:
GENE EXPRESSION IN SV40-TRANSFORMED HUMAN FIBROBLASTS
-
批准号:6267166
-
项目类别:
-
资助金额:$11.95万
-
财政年份:1998
-
负责人:HARVEY L OZER
-
依托单位:
GENE EXPRESSION IN SV40-TRANSFORMED HUMAN FIBROBLASTS
-
批准号:6233925
-
项目类别:
-
资助金额:$12.15万
-
财政年份:1997
-
负责人:HARVEY L OZER
-
依托单位:
IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
-
批准号:3115378
-
项目类别:
-
资助金额:$8.1万
-
财政年份:1991
-
负责人:HARVEY L OZER
-
依托单位:
IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
-
批准号:3115386
-
项目类别:
-
资助金额:$28.06万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
Immortalization of SV40-Transformed Human Cells
-
批准号:6933094
-
项目类别:
-
资助金额:$38.76万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
Immortalization of SV40-Transformed Human Cells
-
批准号:6733496
-
项目类别:
-
资助金额:$38.76万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
IMMORTALIZATION OF SV40 TRANSFORMED HUMAN CELLS
-
批准号:2748485
-
项目类别:
-
资助金额:$41.66万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
-
批准号:3115384
-
项目类别:
-
资助金额:$27.8万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
-
批准号:3115387
-
项目类别:
-
资助金额:$11.22万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
IMMORTALIZATION OF SV40 TRANSFORMED HUMAN CELLS
-
批准号:6598231
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
Immortalization of SV40-Transformed Human Cells
-
批准号:6804446
-
项目类别:
-
资助金额:$38.76万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
-
批准号:3115377
-
项目类别:
-
资助金额:$28.19万
-
财政年份:1988
-
负责人:HARVEY L OZER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:程子译
-
依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
-
批准号:2026JJ81091
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘亮
-
依托单位:
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
-
批准号:2026JJ50010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:应站明
-
依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
-
批准号:JCZRLH202600588
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于基因编辑技术解析丹酚酸B靶向SAMHD1调控心肌线粒体RNA稳态干预心衰的分子机制研究
-
批准号:JCZRLH202601084
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
RNA 结合蛋白HuR与VEGF-D联合调控舌鳞癌侵袭及转移机制的研究
-
批准号:2026JJ80684
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:龚攀
-
依托单位:
基于异质人群多源数据识别单细胞 RNA数量性状风险位点的统计学方法研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:蔡铭轩
-
依托单位:
uN2CpolyG蛋白经ALYREF蛋白介导RNA转运异常在神经元核内包涵体病发病中的作用及机制研究
-
批准号:2026JJ60587
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张思哲
-
依托单位:
病毒非编码RNA多样性图谱构建及其生物发生与致病机制研究
-
批准号:2026JJ60389
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:傅萍
-
依托单位:
核糖核酸酶RNase E与其抑制因子RebA通过液-液相分离调控蓝藻RNA代谢的分子机制
-
批准号:JCZRQNB202600879
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: